knowledge -WSS

knowledge

author：leisure time 2025-10-01 21:40:16 - browse：392

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Time to name cancers by genetics, not organ of origin, expert says

leisure time

WSS

Time to name cancers by genetics, not organ of origin, expert says

General Catalyst, Summa Health deal will turn on physician buy

Vertex non

Doctor of U.S. President Joe Biden says he is fit for duty

ARCH Venture Partners is raising $3 billion for a life sciences fund

Laying a path for careers in science

hotspot

knowledge

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Medicare isn't yet testing food as medicine

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Vertex non

Novavax promises a turnaround & Lilly roils the obesity market

Commercial surrogacy can be ethical, despite pope’s claims

DIEP, the 'gold standard' of breast reconstruction, is under threat

Apple Vision Pro: A first look at health apps on the new VR headset

Trump demands the U.S. pay no more for drugs than other countries … again

FDA drug safety: Singulair case shows systemic surveillance flaws

leisure time

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Elisabeth Bik tackles the widespread issue of research misconduct

Congressmen charge Covid hearing ‘could have been an email’

Apple Vision Pro: A first look at health apps on the new VR headset

Are embryos people? Reproductive medicine's future depends on the answer

Color Health wants to make cancer screenings convenient

leisure time

focus

hotspot

leisure time